Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer

被引:107
|
作者
Hanagiri, Takeshi [1 ]
Sugaya, Masakazu [1 ]
Takenaka, Masaru [1 ]
Oka, Sohich [1 ]
Baba, Tetsuro [1 ]
Shigematsu, Yoshiki [1 ]
Nagata, Yoshika [1 ]
Shimokawa, Hidehiko [1 ]
Uramoto, Hidetaka [1 ]
Takenoyama, Mitsuhiro [1 ]
Yasumoto, Kosei [1 ]
Tanaka, Fumihiro [1 ]
机构
[1] Univ Occupat & Environm Hlth, Sch Med, Dept Surg 2, Yahatanishi Ku, Kitakyushu, Fukuoka 807, Japan
关键词
CYFRA; 21-1; CEA; Surgical resection; Non-small cell lung cancer; Postoperative prognosis; VINORELBINE PLUS CISPLATIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA ANTIGEN; TUMOR-MARKER; SERUM; SCC; ASSOCIATION; RECURRENCE; EXPRESSION; SURVIVAL;
D O I
10.1016/j.lungcan.2011.02.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study investigated the preoperative serum levels of CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Subjects: This study evaluated 341 patients who had undergone a complete resection for stage I NSCLC between 2002 and 2008. Results: The patients included 193 males and 148 females. The mean age of the patients was 69.2 years (range: 19-88). The histological types included 264 adenocarcinomas, 56 squamous cell carcinomas, 11 large cell carcinomas, and 10 other types of carcinoma. A pneumonectomy was performed in 2 patients, a bilobectomy in 7, a lobectomy in 255, a segmentectomy in 46, and partial resection of the lung in 31 patients. The positive rates for CYFRA 21-1 in the adenocarcinoma and squamous cell carcinoma patients were 33.3% and 76.8%, respectively. The positive rates for CEA in adenocarcinoma and squamous cell carcinoma patients were 23.8% and 26.8%, respectively. The 5-year survival rate after surgery in the normal CYFRA 21-1 group and the high CYFRA 21-1 groups were 92.8% and 75.4%, respectively, in the patients with stage I NSCLC. There was a significant difference between the 2 groups (p < 0.0001). The 5-year survival rate according to the serum level of CEA in the patients with stage I NSCLC were 88.3% for the normal group and 76.3% for the high group. In a multivariate analysis using the variables found to be significant prognostic factors in univariate analysis, a high CYFRA 21-1 level was found to be a significant independent prognostic factor (95% confidence interval 1.213-5.442, p = 0.014). Conclusion: A high preoperative CYFRA 21-1 level was a significant independent prognostic factor in patients with stage I NSCLC. The patients with a high CYFRA 21-1 level should carefully followed-up to rule out occult metastasis. Further clinical studies will be necessary to evaluate the efficacy of adjuvant therapy for the patients selected according to this criterion. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:112 / 117
页数:6
相关论文
共 50 条
  • [31] CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy
    Ebert, W
    Muley, T
    ANTICANCER RESEARCH, 1999, 19 (4A) : 2669 - 2672
  • [32] Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients
    Sone, Kazuki
    Oguri, Tetsuya
    Ito, Keima
    Kitamura, Yuki
    Inoue, Yoshitsugu
    Takeuchi, Akira
    Fukuda, Satoshi
    Takakuwa, Osamu
    Maeno, Ken
    Asano, Takamitsu
    Kanemitsu, Yoshihiro
    Ohkubo, Hirotsugu
    Takemura, Masaya
    Ito, Yutaka
    Niimi, Akio
    ANTICANCER RESEARCH, 2017, 37 (09) : 5125 - 5131
  • [33] Prognostic factors in clinical stage I non-small cell lung cancer
    Suzuki, K
    Nagai, K
    Yoshida, J
    Moriyama, E
    Nishimura, M
    Takahashi, K
    Nishiwaki, Y
    ANNALS OF THORACIC SURGERY, 1999, 67 (04): : 927 - 932
  • [34] Prognostic factors in stage I/II non-small cell lung cancer
    Junker, K
    LUNG CANCER, 2001, 33 : S17 - S24
  • [35] Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer
    Zhang, Zhi-Hui
    Han, Yun-Wei
    Liang, Hui
    Wang, Le-Min
    CANCER MEDICINE, 2015, 4 (11): : 1633 - 1638
  • [36] The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Dal Bello, Maria Giovanna
    Filiberti, Rosangela
    Rijavec, Erka
    Genova, Carlo
    Barletta, Giulia
    Rossi, Giovanni
    Biello, Federica
    Distefano, Roberta
    Orengo, Anna Maria
    Alama, Angela
    Coco, Simona
    Vanni, Irene
    Mussap, Michele
    Grossi, Francesco
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S827 - S828
  • [37] Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer
    Niklinski, J
    Furman, M
    Burzykowski, T
    Chyczewski, L
    Laudanski, J
    Chyczewska, E
    Rapellino, M
    BRITISH JOURNAL OF CANCER, 1996, 74 (06) : 956 - 960
  • [38] Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: A prospective study of 116 patients
    Brechot, JM
    Chevret, S
    Nataf, J
    LeGall, C
    Fretault, J
    Rochemaure, J
    Chastang, C
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (03) : 385 - 391
  • [39] The relevance of CEA and CYFRA21-1 as predictive factors in nivolumab treated advanced non-small cell lung cancer (NSCLC) patients
    Dal Bello, M. G.
    Filiberti, R. A.
    Rijavec, E.
    Genova, C.
    Barletta, G.
    Rossi, G.
    Biello, F.
    Distefano, R.
    Orengo, A. M.
    Alama, A.
    Coco, S.
    Vanni, I.
    Tagliamento, M.
    Mussap, M.
    Grossi, F.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 161 - 161
  • [40] Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis -: Comparison with the main clinical and pathological prognostic factors
    Molina, R
    Filella, X
    Augé, JM
    Fuentes, R
    Bover, I
    Rifa, J
    Moreno, V
    Canals, E
    Viñolas, N
    Marquez, A
    Barreiro, E
    Borras, J
    Viladiuc, P
    TUMOR BIOLOGY, 2003, 24 (04) : 209 - 218